Literature DB >> 31397016

Chitinase 3-like 1 drives allergic skin inflammation via Th2 immunity and M2 macrophage activation.

Eun Ji Kwak1, Jung Yeon Hong1, Mi Na Kim1, Soo Yeon Kim1, Seo Hyeong Kim2, Chang Ook Park2, Kyung Won Kim1, Chun Geun Lee3,4, Jack A Elias3, Hye Mi Jee5, Myung Hyun Sohn1.   

Abstract

BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by defective skin barrier and Th2 immune responses. Chitinase 3-like 1 (CHI3L1), also known as breast regression protein 39 (BRP-39) in mice and human homologue YKL-40, plays important roles in Th2 inflammation and allergen sensitization. CHI3L1 has been implicated in a variety of diseases including asthma characterized by inflammation, apoptosis and tissue remodelling, but its role in AD remains elusive.
OBJECTIVE: The aim of this study was to investigate the role of CHI3L1 in the development and progression of AD.
RESULTS: We investigated YKL-40 levels in the serum and skin of AD patients by ELISA and immunofluorescence, respectively. Using a murine model of AD induced by ovalbumin (OVA), we investigated Th2 immune responses, M2 macrophage activation and skin barrier gene expression using wild-type (WT) and BRP-39 null mutant (BRP-39-/- ) mice. YKL-40 level was significantly increased in serum of AD patients. In addition, both mRNA and protein expression levels of BRP-39 were higher in OVA-sensitized WT mice than in control mice. OVA-sensitized BRP-39-/- mice showed decreased epidermal thickness, lower total serum IgE, Th2 cytokine levels and CD4+ effector T cell populations than OVA-sensitized WT mice. Induction of BRP-39 was dominant in dermal macrophages. BRP-39 deficiency was found to be involved in M2 macrophage activation. Consistently, the YKL-40 level in the skin of AD patients was higher than in normal subjects and it was expressed in dermal macrophages. BRP-39 deficiency attenuated dysregulation of skin barrier and tight junction genes. CONCLUSIONS AND CLINICAL RELEVANCE: These findings demonstrate that CHI3L1 mediates the development of AD induced by OVA, affecting Th2 inflammation, M2 macrophage activation and skin barrier function.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  atopic dermatitis; chitinase 3-like 1; skin barrier; type 2 immunity

Mesh:

Substances:

Year:  2019        PMID: 31397016     DOI: 10.1111/cea.13478

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  11 in total

1.  Regulatory effects of miR-138 and RUNX3 on Th1/Th2 balance in peripheral blood of children with cough variant asthma.

Authors:  Zhi-Gang Wang; Gai-Qing Shen; Yu-Huan Huang
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2021-10-15

2.  Potential role of chitinase-3-like protein 1 (CHI3L1/YKL-40) in neurodegeneration and Alzheimer's disease.

Authors:  Kevin Connolly; Mikael Lehoux; Ryan O'Rourke; Benedetta Assetta; Guzide Ayse Erdemir; Jack A Elias; Chun Geun Lee; Yu-Wen Alvin Huang
Journal:  Alzheimers Dement       Date:  2022-03-02       Impact factor: 16.655

3.  Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer.

Authors:  Michelle M Williams; Nicole S Spoelstra; Spencer Arnesen; Kathleen I O'Neill; Jessica L Christenson; Jordan Reese; Kathleen C Torkko; Andrew Goodspeed; Emmanuel Rosas; Toru Hanamura; Sharon B Sams; Zheqi Li; Steffi Oesterreich; Rebecca B Riggins; Britta M Jacobsen; Anthony Elias; Jason Gertz; Jennifer K Richer
Journal:  Cancer Res       Date:  2020-11-12       Impact factor: 13.312

4.  The expression levels of CHI3L1 and IL15Rα correlate with TGM2 in duodenum biopsies of patients with celiac disease.

Authors:  Paola Catrogiovanni; Giuseppe Musumeci; Salvatore Giunta; Rosa Imbesi; Michelino Di Rosa
Journal:  Inflamm Res       Date:  2020-06-04       Impact factor: 6.986

5.  Ubiquitous Overexpression of Chromatin Remodeling Factor SRG3 Exacerbates Atopic Dermatitis in NC/Nga Mice by Enhancing Th2 Immune Responses.

Authors:  Sung Won Lee; Hyun Jung Park; Jungmin Jeon; Yun Hoo Park; Tae-Cheol Kim; Sung Ho Jeon; Rho Hyun Seong; Luc Van Kaer; Seokmann Hong
Journal:  Int J Mol Sci       Date:  2021-02-04       Impact factor: 5.923

Review 6.  Selective IL-13 inhibitors for the treatment of atopic dermatitis.

Authors:  Francisca Gonçalves; Egídio Freitas; Tiago Torres
Journal:  Drugs Context       Date:  2021-03-30

7.  Targeting protumor factor chitinase-3-like-1 secreted by Rab37 vesicles for cancer immunotherapy.

Authors:  Pei-Shan Yang; Min-Hua Yu; Ya-Chin Hou; Chih-Peng Chang; Shao-Chieh Lin; I-Ying Kuo; Pei-Chia Su; Hung-Chi Cheng; Wu-Chou Su; Yan-Shen Shan; Yi-Ching Wang
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600

8.  New therapeutic strategy for atopic dermatitis by targeting CHI3L1/ITGA5 axis.

Authors:  Yong Sun Lee; Ji Eun Yu; Min Ji Kim; Hyeon Joo Ham; Seong Hee Jeon; Jaesuk Yun; Suk-Gil Song; Chong-Kil Lee; Sang Bae Han; Dong Ju Son; Jin Tae Hong
Journal:  Clin Transl Med       Date:  2022-02

9.  Inhibition of Chitinase-3-like-1 by K284-6111 Reduces Atopic Skin Inflammation via Repressing Lactoferrin.

Authors:  Seong Hee Jeon; Yong Sun Lee; In Jun Yeo; Hee Pom Lee; Jaesuk Yoon; Dong Ju Son; Sang-Bae Han; Jin Tae Hong
Journal:  Immune Netw       Date:  2021-06-29       Impact factor: 6.303

10.  Chitinase 3-Like 1 Contributes to Food Allergy via M2 Macrophage Polarization.

Authors:  Eun Gyul Kim; Mi Na Kim; Jung Yeon Hong; Jae Woo Lee; Soo Yeon Kim; Kyung Won Kim; Chun Geun Lee; Jack A Elias; Tae Won Song; Myung Hyun Sohn
Journal:  Allergy Asthma Immunol Res       Date:  2020-11       Impact factor: 5.764

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.